Lantern Pharma's LP-300 Shows 8.3-Month PFS in EGFR L858R Lung Cancer Patients
Event summary
- Lantern Pharma scheduled a Type C meeting with the FDA for mid-May 2026 to discuss protocol amendments for its Phase 2 HARMONIC™ trial of LP-300.
- Emerging data shows LP-300 achieved an 8.3-month median progression-free survival (PFS) in EGFR Exon 21 L858R-mutant NSCLC patients post-TKI therapy.
- The trial's safety data indicates LP-300 adds no significant toxicity to the carboplatin and pemetrexed chemotherapy backbone.
- Lantern proposes focusing future trial enrollment on EGFR Exon 21 L858R patients and increasing LP-300 treatment cycles from 6 to 8.
The big picture
Lantern Pharma's emerging data for LP-300 highlights a potential breakthrough in treating EGFR Exon 21 L858R-mutant NSCLC patients, a subgroup with limited therapeutic options. The company's strategic shift to focus on this mutation aligns with broader trends in precision oncology, where targeted therapies are increasingly tailored to specific genetic profiles. The proposed protocol amendments and FDA meeting reflect Lantern's efforts to navigate the regulatory landscape while positioning LP-300 as a differentiated treatment option in a growing market.
What we're watching
- Regulatory Alignment
- Whether the FDA will concur with Lantern's proposed protocol amendments, which aim to sharpen the trial design around L858R patients.
- Clinical Validation
- How the emerging PFS data for LP-300 will hold up in larger cohorts and whether the observed benefits will be reproducible.
- Commercial Potential
- The pace at which Lantern can leverage the L858R mutation's prevalence in never-smoker populations, particularly in Asia, to expand LP-300's market reach.
Related topics